CHMP recommends Quinsair for treatment of Cystic Fibrosis-pseudomonas aeruginosa-Aptalis/Actavis
On 18 December 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Quinsair from Aptalis/Forest, 240 mg, nebuliser solution intended for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis.
The active substance of Quinsair is levofloxacin, a fluoroquinolone antibacterial: J01MA12, acting by inhibition of bacterial DNA gyrase and topoisomerase IV enzymes.
A pharmacovigilance plan for Quinsair will be implemented as part of the marketing authorisation.Quinsair is known as Aeroquin in the US where it is in Phase III trials.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.